|
Market Closed -
Other stock markets
|
Pre-market 06:13:28 pm | |||
| 22.20 USD | +0.14% |
|
21.32 | -3.94% |
| 10/12 | Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says | MT |
| 09/12 | Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says | MT |
Main competitors
| Capi.($) | Investor | ESG MSCI | Fundamentals | Financial revisions | Global Valuation | Visibility | Consensus | ||
|---|---|---|---|---|---|---|---|---|---|
 | 232.63Cr | BBB | |||||||
| 346.7Cr | - | BB | - | - | ||||
| 39Cr | - | - | - | - | - | - | - | |
| 8.3Cr | - | - | - | - | - | - | - | |
| Average | 156.54Cr | BBB | |||||||
| Weighted average by Cap. | BBB |
- Stock Market
- Equities
- SRPT Stock
- Sector Sarepta Therapeutics, Inc.
- Sector ratings
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition